Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

RCT (n=1,334) found an improved progression free survival after median follow-up of 60.9 months for A+AVD (brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) vs ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) (82.2% vs 75.3%, HR 0.68, 95%CI 0.53-0.87).

The Lancet Haematology